A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group
← catalyst calendarNCT05937750 · readout in 1,350 d
Sponsored by Hansa Biopharma AB (industry) · HNSA.ST — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Other
Enrollment
150estimated
Sites
14
Countries
Austria, Czechia, France +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-03 | actual | When the study began enrolling |
| Primary completion | 2030-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Long Term Efficacy and Safety
Interventions
- Drug: Imlifidase administered in the 20-HMedIdeS-19 (PAES) study — also filed as IdeS, HMED-IdeS, Idefirix
- Other: Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
Primary outcome
what the primary-completion date above is the date OFGraft failure-free survival (%) up to 5 years after imlifidase enabled transplantation (imlifidase cohort only)
measured 5-years after transplantation
Permalink · HNSA.ST's whole pipeline · Catalyst calendar · Every registered study · What changed